This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The End of Blockbuster Drugs

As Pfizer's (PFE) Celebrex safety hiccup was unfolding Friday, I had a running conversation with a fund manager. Over the course of several phone calls and instant messages, this fund manager vented his frustration, arguing that from a medical and scientific standpoint, the Celebrex scare was overblown.

At the proper (low) dosages, Celebrex wasn't causing an increased risk of heart attack or stroke, he argued. And he felt that as long as Pfizer kept the drug on the market (which he was confident would happen), doctors would continue to prescribe it to their patients.

This fund manager is a smart guy, but he's in the dark about what's really going on with Pfizer right now. There is a public hysteria over Celebrex and the entire class of so-called COX-2 inhibitors . People are scared that if they pop a Celebrex, a Vioxx or a Bextra in their mouths, they're going to keel over from a heart attack! Blame the media or the tort lawyers for inciting this fear -- it doesn't matter. Because right now, as far as Wall Street is concerned, Celebrex sales are balanced precariously on a cliff whether or not the drug is ultimately pulled from the market. (Can you imagine a doctor prescribing Celebrex these days?)

Jim Cramer gets it when he asked on Monday why, according to Pfizer, is Celebrex safe enough to sell to the public, but not safe enough to advertise on television? The Food and Drug Administration -- already under withering criticism for what it did, or didn't do, about Merck's (MRK) Vioxx safety problem -- doesn't seem to be in a position to go easy on Pfizer.

In public comments Friday, FDA interim chief Les Crawford said the agency is concerned about the safety of the entire COX-2 drug class, adding that the FDA is recommending that doctors seek alternative therapies to Celebrex for their patients. This doesn't exactly sound like a guy who's looking for a top spot on Pfizer CEO Hank McKinnell's Christmas card list.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs